Terms ending in 2042
Every in-force patent on Astellas US LLC's record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,957,696 | Abiraterone Prodrugs In force · Medium confidence | Astellas US LLC | In force | Medium confidence | |
| US 12,296,026 | Transcription Regulatory Elements and Uses Thereof In force · High confidence | Astellas Gene Therapies, Inc. | In force | High confidence | |
| US 12,514,858 | CD38 Inhibitors In force · High confidence | Astellas Engineered Small Molecules US, Incorporated | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.